Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Abata Therapeutics is raising $95,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Samantha Singer played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Abata Therapeutics
We are bringing an entirely new approach to the treatment of autoimmune disease by engineering Tregs as targeted therapies that stop immune-mediated destruction, restore homeostasis a state of harmony and promote repair in the affected tissues. In addition to our lead program in progressive MS, Abata has early programs in Type 1 Diabetes (T1D) and inclusion body myositis (IBM). We bring together industry experts and deeply engaged pioneers in Treg biology, T cell receptor and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers. We are bold in our mission and purpose and aim for nothing less than a transformative impact on peoples lives.

To learn more about Abata Therapeutics, visit http://abatatx.com/

Contact:
Samantha Singer, President and Chief Executive Officer
617-585-2000
ssinger@abatatx.com
https://www.linkedin.com/in/samanthasinger/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved